FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion
The FDA has granted an accelerated approval to mobocertinib for the treatment of locally advanced or metastatic nonsmall cell lung cancer with a specific type of EGFR mutation.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer